There are 2789 resources available
916P - Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study
Presenter: Leonardo Muratori
Session: ePoster Display
917P - Head and neck cancer patients under (chemo-)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial
Presenter: Anna Finger
Session: ePoster Display
CN3 - The effect of using interactive mobile application for management of chemotherapy induced nausea and vomiting in children: Randomized controlled study
Presenter: Remziye Semerci
Session: ePoster Display
918P - Impact of locally advanced head and neck cancer treatment: Is there a role for exercise? FIT4TREAT
Presenter: Ines Leao
Session: ePoster Display
919P - Survival impact of nutritional status of locally advanced head and neck cancer squamous cell carcinoma (HNSCC) patients treated with chemoradiotherapy: A prospective observational study
Presenter: Ratchadakorn Meesart
Session: ePoster Display
920P - The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)
Presenter: Simona Guerriero
Session: ePoster Display
921P - Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation
Presenter: VINAYAKUMAR MUTTAGI
Session: ePoster Display
922P - Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Presenter: Michael Pogorzelski
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display
924P - HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany
Presenter: Harald Müller-Huesmann
Session: ePoster Display